Our R&D Team

Learn more about the backgrounds, scientific pursuits and personal interests of members of our R&D team. These individuals are committed to pursuing Bristol-Myers Squibb’s goal of discovering, developing and delivering transformational medicines to patients.
Beatrice Anduze-Faris, M.D.

Head of Global Clinical Compliance & Continuous Improvement, Global Clinical Operations

Bryan (Bo) Barnhart, Ph.D.

Senior Director, Immuno-Oncology, Discovery

Percy Carter, MBA, Ph.D.

Head of Discovery Chemistry and Molecular Technologies, Drug Discovery Research

Edgar Charles, M.D.

Clinical Development Lead, pegylated FGF21

Binodh DeSilva, Ph.D.

Head of Analytical and Bioanalytical Operations, Pharmaceutical Development

Evan Janovitz, DVM, Ph.D., DACVP

Director of Pathology, Discovery Toxicology

Charlotte Jones-Burton, M.D., M.S.

Global Clinical Program Lead, Cardiovascular Marketed Products

Alan Korman, Ph.D.

Vice President, Immuno-Oncology Discovery

Michael C. Montalto, Ph.D.

Executive Director, Pathology & Clinical Biomarker Laboratories, Translational Medicine

Ryan Moslin, Ph.D.

Senior Research Investigator, Early Immunology Discovery

Mike Quigley, Ph.D.

Executive Director and Co-Lead, Immuno-Oncology Resistance Biology

Luisa Salter-Cid, Ph.D.

Head of Immunology Discovery, Biology and Genomics

Mark Selby, Ph.D.

Senior Director, Immuno-oncology Discovery

John Throup, BSc, Ph.D.

Development Lead, Immunoscience R&D